DEFB126

Across TCGA pan-cancer cohorts, DEFB126 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated DEFB126 data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher DEFB126 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB126 expression acts as an unfavorable survival marker, although some lineages such as LUSC and SCLC show a favorable association.

LIHC, UCS, and ACC are the cancer types where DEFB126 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.520	0.748	<.001	117	view →
UCS	OS	Tertile	All	0.508	0.845	.001	70	view →
ACC	DFS	Tertile	II,III,IV	0.108	0.565	<.001	63	view →
LUSC	OS	Tertile	All	0.506	0.350	.009	31	view →
BLCA	OS	Median	IV	0.229	0.581	.004	21	view →
SCLC	OS	Tertile	II,III,IV	0.881	0.551	.014	21	view →
PRAD	DFS	Tertile	All	0.841	0.542	.025	20	view →
ESCA	DFS	Tertile	All	0.903	0.444	.017	19	view →
DLBC	DFS	Tertile	All	0.399	0.796	.032	18	view →
READ	DFS	Tertile	IV	0.179	0.936	.010	15	view →
LUAD	DFS	Tertile	All	0.734	0.839	.012	15	view →
KIRP	OS	Tertile	II,III,IV	0.122	0.625	.035	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

DEFB126–LIHC (OS)

Open the LIHC breakdown →